Potential role of various dosimetric quality indicators in prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 3, 1999, Pages 717-724

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Dorsey, Anthony T ^a   Lief, Jonathan H ^a,c  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

Dosimetry; Prostate brachytherapy; Quality indicators

Indexed keywords

IODINE; PALLADIUM;

AGED; ARTICLE; BRACHYTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DOSIMETRY; ECHOGRAPHY; FOLLOW UP; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; PERINEUM; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION FIELD; RECTUM; URETHRA;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0033025215     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00067-X     Document Type: Article

References (36)

1. Blasko J.C., Wallner K., Grimm P.D., Ragde H. Prostate specific antigen based disease control following ultrasound guided iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
2. Wallner K., Roy J., Zelefsky M., Fuks Z., Harrison L. Short term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 30:1994;405-409.
3. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal I-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
4. Dattoli M., Wallner K., Sorace R., Koval J., Cash J., Acosta R., Brown C., Etheridge J., Binder M., Brunelle R., Kirwan N., Sanches S., Stein D., Wasserman S. Pd-103 brachytherapy and external beam radiation therapy for clinically localized high risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
5. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Sem Rad Oncol. 3:1993;240-249.
6. Blasko J.C., Ragde H., Cavanagh W., Sylvester J., Grimm P.D. Long term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys. 36:1996;198.
7. Ragde H., Blasko J.C., Grimm P.D., Kenny G.M., Sylvester J.E., Hoak D.C., Landin K., Cavanagh W. Interstitial I-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer. Cancer. 80:1997;442-453.
8. Dattoli M.J., Wallner K.E., Cash J.C., Ross R.E., Koval J.M., Source R.A. Pd-103 brachytherapy for clinical T1/T2 prostate carcinomas. Int J Radiat Oncol Biol Phys. 39:1997;221.
9. Critz F., Levinson K., Williams W., Holladay D., Holladay C., Griffin V. Prostate specific antigen nadir of 0.5ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology. 49:1997;668-672.
10. Critz F., Levinson K., Williams W., Holladay D. Prostate specific antigen nadir The optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
11. Stokes S., Real J., Adams P., Clements J., Duertzer S., Kan W. Transperineal ultrasound guided radioactive seed implantation for organ confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 37:(2):1997;337-341.
12. Willins J., Wallner K. CT based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;347-353.
13. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
14. Merrick G.S., Butler W.M., Dorsey A.T., Walbert H.L. Prostatic conformal brachytherapy I-125/Pd-103 post-operative dosimetric analysis . Rad Onc Invest. 5:1997;305-313.
15. Merrick G.S., Butler W.M., Dorsey A.T., Walbert H.L. The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy. Rad Onc Invest. 6:1998;182-190.
16. Prestidge B.R., Bice W.S., Prete J.J., Buchholz T.A. A dose volume analysis of permanent transperineal prostatic brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;238.
17. Prestidge B.R., Bice W.S., Kiefer E.T., Prete J.J. Timing of computed tomography based post-implant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;1111-1115.
18. Moerland M.A., Wijrdeman H.K., Beersma R., Bakker C.J.G., Batterman J.J. Evaluation of permanent I-125 prostate implants using radiography and magnetic imaging. Int J Radiat Oncol Biol Phys. 37:1997;927-933.
19. Stock R.G., Stone N.N., DeWyngaert J.K., Lavagnini P., Unger P.D. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage carcinoma. Cancer. 77:1996;2386-2392.
20. Stock R.G., Stone N.N., Tabert A., DeWyngaert J.K. Dose response for iodine-125 prostate implants. Int J Radiat Oncol Biol Phys. 39:(2 Supp):1997;221.
21. Stock R.G., Stone N.N., Tabert A., Iannuzzi C., DeWyngaert J.K. A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:(1):1998;101-108.
22. Bice W.S., Prestidge B.R. A review of postimplant quality assessment in permanent transperineal interstitial prostate brachytherapy. J Brachytherapy Int. 13:1997;297-313.
23. Nag S. ABS Prostate Brachytherapy Consensus Statement. American Brachytherapy Society Annual Meeting. Albuquerque, New Mexico, May 31, 1998.
24. Saw C.B., Suntharalingam N. Quantitative assessment of interstitial implants. Int J Radiat Oncol Biol Phys. 20:1991;135-139.
25. Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ. Rectal dosimetric analysis following prostate conformal brachytherapy. Int J Radiat Oncol Biol Phys, 43:1021-1027.
26. Butler W.M., Dorsey A.T., Nelson K.R., Merrick G.S. Quality assurance calibration of I-125 rapid strand in a sterile environment. Int J Radiat Oncol Biol Phys. 41:(1):1998;217-222.
27. Merrick G.S., Butler W.M., Farthing W.H., Dorsey A.T., Adamovich E. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachytherapy Int. 14:1998;113-121.
28. Nath R., Anderson L.L., Luxton G., Weaver K.A., Williamson J.F., Meigooni A.S. Dosimetry of interstitial brachytherapy sources recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 . Med Phys. 22:1995;209-234.
29. Roy J.N., Wallner K.E., Harrington B.A., Ling C.C., Anderson L.L. A CT based evaluation method for permanent implants Application to prostate . Int J Radiat Oncol Biol Phys. 26:1993;163-169.
30. Fuks Z., Leibel S.A., Wallner K.E., Begg C.B., Fair W.R., Anderson L.L., Hilaris B.S., Whitmore W.F. The effect of local control on metastatic dissemination in carcinoma of the prostate long term results in patients with I-125 implantation . Int J Radiat Oncol Biol Phys. 21:1991;537-547.
31. Morton J.D., Peschel R.E. Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys. 14:1988;1153-1157.
32. Ling C.C. Permanent implants using Au-198, Pd-103, and I-125 radiobiological considerations based on the linear quadratic model . Int J Radiat Oncol Biol Phys. 23:1992;81-87.
33. 125I prostate implants. Int J Radiat Oncol Biol Phys. 34:1996;717-725.
34. Waterman F.M., Yue N., Reisinger S., Dicker A., Corn B.W. Effect of edema on the post-implant dosimetry of an I-125 prostate implant A case study . Int J Radiat Oncol Biol Phys. 38:1997;335-339.
35. Waterman F.M., Yue N., Corn B.W., Dicker A.P. Edema associated with I-125 or Pd-103 prostate brachytherapy and its effect on post-implant dosimetry An analysis based on serial CT acquisition . Int J Radiat Oncol Biol Phys. 39:(2 Suppl):1997;220.
36. Butler WM, Merrick GS, Lief JH, Dorsey AT. Isotope choice and the effect of edema on prostate brachytherapy dosimetry. submitted.